BGNE - BeiGene: Debating On Finally Establishing A Position

2024-01-26 08:25:42 ET

Summary

• BeiGene has an impressive pipeline and global market penetration, offering significant upside potential.
• The company's recent pipeline advancements and successful clinical trials have reduced its valuation and made it more attractive.
• BeiGene's growth drivers include its hematology franchise, strategic collaborations, and expansion efforts.

BeiGene, Ltd. (BGNE) has been an alluring biotech ticker for quite some time, due to their impressive pipeline, strategic partnerships, and global market penetration. BeiGene's recent pipeline advancements, coupled with successful clinical trials hold a lot of promise both clinically and commercially, offering significant upside potential in the coming years. Yet, I have been weary of the ticker's valuation over the years, and have avoided establishing a position numerous times. However, BGNE has been under strong selling pressure going from over $400 per share to around $160 per share in only a few years. This sell-off has taken the edge off BGNE's premium valuation and has forced me to reevaluate establishing a BGNE pilot position at some point in 2024....

For further details see: